A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Participants With Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase of Trial: Phase III
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Nivolumab (Primary) ; Cetuximab; Cisplatin
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 10 Jan 2018 Planned End Date changed from 20 Oct 2022 to 11 Nov 2022.
- 10 Jan 2018 Planned primary completion date changed from 19 Oct 2022 to 10 Nov 2022.
- 05 Dec 2017 Planned End Date changed from 22 Oct 2025 to 20 Oct 2022.